

REVIEW

Amyloid imaging and memory change for prediction of cognitive impairment

Susan M Resnick^{*1} and Jitka Sojkova^{1,2}

Abstract

PET radiotracers for *in vivo* measurement of β -amyloid ($A\beta$) deposition throughout the brain are contributing to early detection of the neuropathology associated with Alzheimer's disease and enhancing prediction of individuals most likely to develop cognitive impairment and dementia. However, the fact that 30 to 50% of cognitively normal older adults have varying but detectable levels of $A\beta$ poses challenges and opportunities in using amyloid imaging in research and clinical applications. In this review, we summarize studies of the relationship between $A\beta$ burden and cognitive status in impaired and unimpaired individuals and the relationship between $A\beta$ burden and cognitive function. We conclude by operationalizing the way in which information on imaging-assessed $A\beta$ burden and cognitive performance can be used jointly to improve prediction of clinical outcomes, to enhance understanding of the role of $A\beta$ deposition in cognitive impairment, and to identify factors that promote cognitive resilience in the presence of $A\beta$.

The development of positron emission tomography (PET) amyloid imaging radiotracers has allowed the *in vivo* measurement of fibrillar β -amyloid ($A\beta$) throughout the brain. Amyloid imaging is contributing to the early detection of pathology and diagnosis of Alzheimer's disease (AD), to the selection and therapeutic monitoring of patients in clinical trials, and to differential diagnosis among dementia subtypes. In addition, it is enhancing our understanding of the role of $A\beta$ in the temporal course of disease by allowing prospective assessment of early pathological changes and the cognitive correlates of these changes in $A\beta$ deposition. PET imaging of fibrillar


$A\beta$ provides many opportunities for early diagnosis of cognitive impairment and the understanding of disease progression, but the prediction of clinical outcomes in cognitively unimpaired individuals remains challenging.

The large percentage of individuals who have substantial levels of $A\beta$ but remain cognitively normal is a potential limitation in the use of amyloid imaging for prediction of clinical outcomes. Thirty to fifty percent of individuals who are clinically normal at death have sufficient $A\beta$ plaques at autopsy to meet pathological criteria for AD [1,2]. Similarly, PET imaging studies also show that about 30% [3-7] of cognitively normal individuals have varying levels of increased $A\beta$ on imaging. Some investigators argue that cognitively normal individuals with AD pathology are in a preclinical stage of AD [8-10]. However, we [11] and others [12] have shown that antemortem cognitive change in this group of 'asymptomatic AD' individuals does not differ significantly from cognitively normal individuals without AD pathology at autopsy, in contrast to the marked memory decline evident in those who develop subsequent cognitive impairment (Figure 1a).

The challenge posed by these asymptomatic AD individuals in the application of PET $A\beta$ imaging for clinical diagnosis has led some to question whether these tools will be useful in prediction of clinical outcomes. Individuals with elevated $A\beta$ on PET imaging may not have passed fully through the risk period for AD and represent a heterogeneous group, with some at increased risk for cognitive impairment and others likely to remain healthy (as represented by the autopsy-defined asymptomatic AD group). In this paper, we suggest ways in which information from PET amyloid imaging can be used in combination with cognitive change to improve the utility of these measures for prediction of cognitive decline and impairment and to identify factors that promote cognitive resilience in the presence of $A\beta$ pathology. We first review current evidence demonstrating differences in imaging-assessed $A\beta$ burden among groups of AD, mild cognitive impairment (MCI) [13], and cognitively normal (CN) individuals. Next, we review cross-sectional and longitudinal studies of associations between $A\beta$ deposition and cognitive performance. Finally, we conclude

*Correspondence: resnicks@grc.nia.nih.gov

¹Laboratory of Behavioral Neuroscience, NIH Biomedical Research Center, National Institute on Aging, IRP, 251 Bayview Blvd, Room 4B335, Baltimore, MD 21224, USA
Full list of author information is available at the end of the article



with a discussion of what amyloid imaging in conjunction with cognitive performance can and cannot tell us about prediction of cognitive impairment and resilience. We highlight how information from imaging and neuropsychological assessments can be used in combination to improve prediction of clinical outcomes and to enhance our understanding of the cognitive correlates of A β deposition and progression.

Amyloid imaging in cognitive impairment and in healthy older adults

Imaging with the radioligand [^{11}C]Pittsburgh Compound-B (PiB) has provided strong evidence of group differences between cognitively impaired (AD and MCI) and normal (CN) older adults in global as well as regional measures of A β deposition (for review, see [14]). It is noteworthy that the level of A β in MCI individuals who are PiB-positive approaches the level in AD, suggesting either a plateau [15] or a low rate [16] of A β accumulation after the appearance of clinical symptoms. Frontal, lateral temporal, and parietal regions show consistent patterns of elevated A β in those with cognitive impairment compared with healthy older adults, with more variable findings with respect to group differences in the occipital and striatal regions (for review, see [14]). These global and regional patterns of differences between impaired and CN individuals are generally consistent across a variety of PET amyloid radiotracers. The majority of studies to date have used PiB, but a number of [^{18}F] radiotracers for amyloid imaging recently have become available and have been applied in imaging studies of AD. These include Florbetaben (BAY94-9172),

Flutemetamol (GE067) and Florbetapir (AV-45), and all show differences between AD patients and controls that are similar in distribution to group differences using PiB [17-19]. Additional studies are required to provide information on long-term predictive utility of these amyloid imaging tracers, especially in the case of MCI and preclinical AD in asymptomatic individuals. However, the availability of [^{18}F] ligands, which have a 110-minute half-life and can be produced for regional distribution, will allow more widespread research and potential clinical applications compared to [^{11}C] ligands, which have a 20-minute half-life requiring on-site radiopharmaceutical production.

Another PET radiotracer that has been used to evaluate AD pathology is [^{18}F]FDDNP. [^{18}F]FDDNP differs from the other amyloid imaging compounds in several ways. It labels plaques and tangles, as well as alpha-synuclein [20]. Furthermore, the radioactivity signal from this tracer is lower than the signal achieved with more specific A β radiotracers, leading to difficulties in quantification [21]. However, an interesting application of this tracer is the potential use of subtraction measures to highlight non-amyloid pathology [22]. By using multiple radiotracers, [^{18}F]FDDNP shows additional binding in the hippocampal formation compared to PiB, perhaps reflecting neurofibrillary tangle pathology [22].

Despite consistent group differences between impaired and CN individuals, amyloid imaging compounds show varying levels of elevated A β across individuals. In studies with PiB, attempts have been made to define values for a PiB positive study indicating elevated A β burden. A variety of cut-points have been used (for

review, see [14]), but these are dependent on the specific method used for quantification - for example, standard uptake value ratio (SUVR) versus dynamic modeling of the time course of radioactivity in brain. Both cut-points and approaches that examine A β as a continuous measure have been used to determine relationships with cognitive status.

Amyloid imaging may be especially useful in distinguishing between individuals with MCI who will progress to dementia and AD versus those who will not progress to dementia [23-25]. MCI represents a heterogeneous group, with individuals showing either AD-like levels of A β deposition or CN-like levels of A β deposition [25-28]. Approximately one-half of individuals with amnesic MCI [25,29], characterized by memory impairment, have elevated A β on imaging and have an increased risk of conversion to AD (see below). MCI individuals without elevated A β have a lower likelihood of progression to AD [24,25]. These individuals may be cases of misdiagnosis, may have different conditions that interfere with cognitive function, or may be false negatives on imaging due to the fact that current radiotracers do not label all A β isoforms [30].

Variability in imaging-assessed amyloid burden is also apparent in older cognitively healthy adults. As noted above, the proportion of PiB-positive individuals has ranged from 20% in a study by Mintun and colleagues [5] to 47% in the multicenter study performed through the Alzheimer's Disease Neuroimaging Initiative [4]. Cognitively healthy PiB-positive individuals show a range of values of PiB that are clearly detectable on imaging but are typically below those observed in AD. To date, the primary factors associated with increased A β burden in CN individuals are older age and Apolipoprotein E (APOE) ϵ 4 genotype [7,31]. For example, in the Australian Imaging, Biomarker, and Lifestyle (AIBL) study of 177 healthy controls, 33% of healthy controls were PiB-positive, with a rate of 65% in individuals older than 80 years compared with 18% in individuals aged 60 to 69 years [7,31]. Moreover, the rate of elevated PiB binding was more than double in APOE ϵ 4 gene carriers (49%) compared with noncarriers (21%) [7]. Cognitively healthy individuals with elevated amyloid burden likely represent a heterogeneous group with respect to long-term outcome. While some of these individuals will progress to cognitive impairment and AD, others will remain resilient in the face of pathology. The latter group may parallel the group we have called asymptomatic AD at autopsy (and others have called high pathology controls or preclinical AD), because they do not show accelerated cognitive decline despite substantial amyloid pathology [11]. Some investigators attribute this resilience to 'cognitive reserve' [32-34], implying greater neural complexity or plasticity at baseline, but the resilience may also reflect a more general capacity to regain homeostasis

across body systems in the face of a variety of age-associated insults, including A β deposition.

Amyloid imaging and cognitive performance

Investigations of the associations between *in vivo* measurement of amyloid burden and cognition are necessary to determine the extent and conditions under which elevated amyloid burden is associated with cognitive decline. When data are combined across groups of individuals with AD, MCI and CN older adults, higher A β burden is correlated with lower episodic memory performance [21,28,35,36]. These associations are also evident in analyses pooling MCI and AD together [37] and in studies pooling CN and AD together [33,38]. Correlations between A β burden and performance in non-memory cognitive domains also have been identified in analyses pooling groups of impaired and unimpaired individuals [33,38]. In one study, correlations across diagnostic groups suggested that increased frontal PiB is associated with lower memory whereas increased parietal PiB is associated with lower performance on non-memory functions [36].

Associations between *in vivo* neuropathology and cognitive performance across combined groups of impaired and unimpaired individuals also have been reported using [18 F]FDDNP as the radiotracer [20,39]. In addition to inverse associations between [18 F]FDDNP binding and verbal paired associate memory when CN and MCI individuals were combined, [18 F]FDDNP was also inversely associated with performance on other cognitive measures, including mental status and digit recall, across all groups [20]. Spatial associations of [18 F]FDDNP binding with lower performance on tests of episodic memory and frontal lobe function across groups localized to entorhinal, lateral temporal, parietal, orbitofrontal and dorsolateral prefrontal cortex [39]. Mesial temporal associations with [18 F]FDDNP may reflect sensitivity to neurofibrillary tangles in these regions.

Although associations between PET imaging measures of neuropathology and memory performance are evident in analyses combining impaired and unimpaired individuals, relationships with memory performance within a diagnostic group are more complex (Tables 1 and 2). As summarized in Table 1, the correlations between cross-sectional measures of A β burden using PiB and cognitive performance in AD patients tend to be absent to weak [28,35,37,40]. In MCI, some but not all studies indicate that higher A β burden is associated with lower performance on tests of episodic memory [35,37,41]. A recent study from a larger cohort of 57 MCI participants from the AIBL study on aging showed only a trend to a relationship between higher neocortical A β burden and lower long delay free recall performance on the California Verbal Learning Test, a measure of verbal memory [7].

Table 1. Cross-sectional associations between PiB-assessed β -amyloid burden and cognition in AD and MCI

Study	Year	Sample ^a	Number of subjects ^a	Mean age (SD)	Method	Associations between PiB retention and cognitive function
Furst <i>et al.</i> [40]	2010	AD	39	68.3 (10.5)	DVR	No association with MMSE or CDR-SOB
Forsberg <i>et al.</i> [37]	2010	AD	37	67.5 (9.2)	SUVR	Higher PiB in bilateral frontal cortices and posterior cingulate gyrus weakly associated with lower verbal memory (RAVLT) in AD alone
Grimmer <i>et al.</i> [54]	2009	AD with AD-typical FDG scan	32	66.9 (8.5)	SUVR	Higher PiB in bilateral frontal and anterior cingulate cortex, and lentiform nucleus ($P \leq 0.05$) associated with higher CDR-SOB
Rowe <i>et al.</i> [28]	2007	AD	17	74.0 (11.3)	DVR	No significant association with long delay verbal recall (CVLT) or MMSE
Pike <i>et al.</i> [35]	2007	AD	31	74.8 (10.2)	SUVR	No association with composite score of episodic memory
Rowe <i>et al.</i> [7]	2010	MCI	57	75.5 (7.5)	SUVR	Higher PiB shows trend with lower long delay verbal recall (CVLT; $r = -0.24$, $P = 0.07$)
Wolk <i>et al.</i> [25]	2009	MCI	26	70.2 (8.8)	DVR	PiB-positive aMCI have lower verbal delayed recall than PiB-negative aMCI ($P < 0.01$) but PiB-positive were also substantially older
Lowe <i>et al.</i> [29]	2009	MCI	23	82 (aMCI-), 73 (aMCI+)	SUVR	No significant memory difference between aMCI-negative and aMCI-positive (but aMCI-negative substantially older)
Mormino <i>et al.</i> [41]	2009	PiB+ MCI	39	75.0 (7.9)	DVR	Higher PiB associated with lower verbal delayed recall (RAVLT; $P = 0.05$)
Forsberg <i>et al.</i> [23]	2008	MCI	21	63.3 (7.8)	SUVR	Higher PiB in posterior cingulate, frontal, and temporal cortex ($P \leq 0.05$) associated with lower composite score of episodic memory
Pike <i>et al.</i> [35]	2007	MCI	33	70.7(9.6)	SUVR	Higher PiB associated with lower composite score of episodic memory ($r = -0.6$, $P < 0.001$) and remains significant when limited to aMCI

^aIn some cases a study subsample. AD, Alzheimer's disease; aMCI, amnesic MCI; CDR-SOB, Clinical Dementia Rating scale Sum of Boxes; CVLT, California Verbal Learning Test; DVR, distribution volume ratio; FDG, fluorodeoxyglucose; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; PiB, [¹¹C]Pittsburgh Compound-B; RAVLT, Rey Auditory Verbal Learning Test; SD, standard deviation; SUVR, standard uptake value ratio.

Associations between A β and cognitive performance are even more variable in studies of CN individuals. Table 2 summarizes findings from cross-sectional studies of CN older adults. Several investigations have shown negative cross-sectional correlations between PiB retention and measures of episodic memory [19,41,42], and one study indicated that cognitive reserve, measured by the National Adult Reading Test, may modify this association [33]. However, the largest study of 177 CN adults found no significant cross-sectional correlations with episodic memory [7], suggesting that a few PiB-positive individuals may have a large influence on findings in smaller samples. The varied results across studies highlight the complexity of the relationship between cognitive performance and amyloid deposition at the earliest stages of cognitive decline.

The few longitudinal investigations of cognitive change in relation to A β burden have more consistently shown associations for cognitively healthy individuals (Table 2). For example, Villemagne and colleagues [43] reported that greater decline in word list recall was associated with higher A β deposition in nondemented elderly who ultimately progressed to MCI/AD but not in individuals who remained cognitively normal [43]. Storandt and colleagues [42] found that elevated A β burden was associated with greater longitudinal decline in episodic and working memory, as well as visuospatial ability, and we [6] reported that higher A β was associated with

greater longitudinal decline in verbal memory (Figure 1b), executive function and mental status, but not visual memory. Our observations of significant relationships between higher PiB retention and greater cognitive decline in cognitively healthy individuals appear at first glance to conflict with our autopsy findings [11] showing similar longitudinal cognitive trajectories in older adults with and without AD pathology (Figure 1a,b). However, participants in imaging studies are younger and have not passed fully through the risk period for cognitive decline. Thus, cognitively healthy individuals with elevated A β on imaging include those who are in a preclinical phase of AD as well as those who will be resilient and maintain cognitive health.

Amyloid imaging and cognition in prediction of Alzheimer's disease

There are two ways that amyloid imaging may be useful in combination with cognition in prediction of the likelihood of developing AD. The first involves using amyloid imaging to distinguish among mildly impaired individuals to predict who is likely to progress and who is more likely to remain stable. Table 3 describes the results of initial attempts to use amyloid imaging in predicting outcomes in MCI. The second application combines information on longitudinal cognitive decline with A β status to determine which cognitively healthy individuals are at highest risk for progression to impairment and AD.

Table 2. Associations between β -amyloid burden and cognition in cognitively normal individuals

Study	Year	Radiotracer	Sample ^a	Number of subjects ^a	Mean age (SD)	Method	Associations between amyloid imaging and cognitive function
Cross-sectional measures of concurrent β -amyloid load and cognition							
Rowe <i>et al.</i> [7]	2010	PiB	CN	177	71.6 (7.4)	SUVR	No association with long delay verbal recall (CVLT) No difference in long delay verbal recall between those with high versus low PiB binding
Rentz <i>et al.</i> [33]	2010	PiB	CN	66	73.9 (8.1)	DVR	No main effect of precuneus PiB on cognitive function Higher precuneus PiB associated with lower cued (but not free recall) and canonical variate score in CN individuals with low but not high cognitive reserve measured by AMNART
Storandt <i>et al.</i> [42]	2009	PiB	CN	135	PiB- 74.3 (6.2) PiB+ 75.4 (6.3)	BP	No association with global, verbal, spatial, or working memory composites or individual cognitive measures
Braskie <i>et al.</i> [39]	2010	[¹⁸ F]FDDNP	CN	10	73 (10.4)	DVR	Higher [¹⁸ F]FDDNP in right frontal and some parietal areas associated with lower composite cognitive score
Mormino <i>et al.</i> [41]	2009	PiB	CN ^b	20	72.3 (6.0)	SUVR, DVR	Higher PiB associated with lower episodic memory composite score ($P < 0.01$)
Mormino <i>et al.</i> [41]	2009	PiB	CN ^c	17	78.5 (5.4)	SUVR, DVR	No associations with episodic memory composite score
Rowe <i>et al.</i> [28]	2007	PiB	CN	27	72.6 (6.9)	DVR	No difference in cognitive performance between PiB-positive and PiB-negative
Pike <i>et al.</i> [35]	2007	PiB	CN	32	71.7 (6.6)	SUVR	Higher PiB associated with lower episodic memory composite score ($r = -0.38$, $P < 0.05$) PiB-positive compared with PiB-negative had lower episodic memory composite score ($P < 0.05$)
Cross-sectional measures of β -amyloid load and longitudinal measures of cognition							
Resnick <i>et al.</i> [6]	2010	PiB	CN	57 (6 CDR = 0.5)	78.8 (6.2)	DVR	Higher PiB associated with greater decline in immediate and delayed verbal recall and MMSE (all $P \leq 0.01$) but not visual memory Associations most pronounced for frontal and lateral temporal cortex, as well as putamen
Storandt <i>et al.</i> [42]	2009	PiB	CN	135	PiB- 74.3 (6.2) PiB+ 75.4 (6.3)	BP	Higher PiB associated with greater decline in working memory and visuospatial ability
Villemagne <i>et al.</i> [43]	2008	PiB	Stable (S), declining (D)	24 S, 10 D	S 71.7 (6.7) D 75.5 (4.4)	SUVR	Higher PiB associated with greater decline in word-list recall ($r = -0.78$) in decliners only

^aIn some cases a study subsample. ^bBerkeley Aging Study. ^cAlzheimer's Disease Neuroimaging Initiative (ADNI) cohort. AMNART, American National Adult Reading Test; BP, binding potential; CDR, Clinical Dementia Rating scale; CN, cognitively normal; CVLT, California Verbal Learning Test; DVR, distribution volume ratio; MMSE, Mini-Mental State Examination; PiB, [¹¹C]Pittsburgh Compound-B; RAVLT, Rey Auditory Verbal Learning Test; SD, standard deviation; SUVR, standard uptake value ratio.

In MCI, A β burden assessed by PiB PET has been helpful in distinguishing between individuals who will convert to AD and those who will remain stable [23-25] or develop other forms of dementia. Rates of conversion to AD in MCI individuals with a positive amyloid imaging scan are substantially higher than those with a negative PiB scan, with the latter showing less than 10% rates of conversion over 3 years [24,25]. As described in Table 3, MCI converters may also have different patterns of PiB amyloid deposition compared to MCI non-converters [24], with higher PiB retention in posterior cingulate [23,44] and frontal [44] regions. Okello and colleagues [24] identified a subset of PiB-positive MCI individuals who rapidly progressed to AD. Compared to PiB-positive slower MCI converters and nonconverters, the rapid converters had higher PiB retention in anterior cingulate, frontal, and lateral temporal cortices. In addition, the presence of the APOE ϵ 4 allele in PiB-positive MCI

individuals was associated with higher rates of conversion to AD [24].

In CN adults, consideration of A β burden alone showed that risk for AD in PiB-positive individuals was 4.8 times that in PiB-negative CN individuals over a 2.4-year follow-up [45] (Table 3). However, no studies to date have combined PET measures of A β burden with cognitive performance for prediction of AD risk in CN individuals. In our concluding comments, we operationalize the way that cognitive performance, especially on episodic memory tests, can be used in combination with A β burden to further increase prediction of CN individuals who are likely to develop AD versus remain healthy.

Conclusion

The ability to image brain A β *in vivo* is advancing our understanding of the neurobiology of cognitive impairment and holds promise as a tool that will contribute to

Table 3. Amyloid imaging and prediction of conversion to Alzheimer's disease

Study	Year	Radiotracer	Sample ^a	Number of subjects ^a	Mean age (SD)	Method	Findings
Okello <i>et al.</i> [24]	2009	PiB	MCI	31	69.4 (7.9)	SUVr	82% PiB-positive MCI convert to AD compared to 7% of PiB-negative MCI 47% PiB-positive MCI who convert to AD within 1 year have higher PiB in anterior cingulate and frontal cortex ($P < 0.05$), APOE $\epsilon 4$ is associated with faster conversion rates in PiB-positive MCI ($P < 0.05$)
Wolk <i>et al.</i> [25]	2009	PiB	MCI	26 (23 with follow-up)	70.2 (8.8)	DVR	38% PiB-positive MCI but no PiB- convert to AD over 22 months
Morris <i>et al.</i> [45]	2009	PiB	CN	159	71.5 (8.6)	BP	Higher PiB retention predicts progression from CDR 0 to MCI (hazard ratio = 2.74) and AD (hazard ratio = 4.85) over mean 2.4 years
Koivunen <i>et al.</i> [44]	2008	PiB	aMCI	15	71.1 (7.2)	SUVr, DVR	Elevated PiB in six converters in posterior cingulate and frontal cortex as well as elevated neocortical score
Forsberg <i>et al.</i> [23]	2008	PiB	MCI	21	63.3 (7.8)	SUVr	Higher PiB retention in frontal, parietal, and temporal cortices ($P < 0.01$) in MCI converters than CN individuals Higher PiB retention in posterior cingulate gyrus in MCI converters than MCI nonconverters ($P < 0.01$) No difference in PiB retention between MCI converters and AD
Small <i>et al.</i> [20]	2006	[¹⁸ F]FDDNP	AD, MCI, CN	4 MCI, 8 CN	NA for this subset	DVR	Three disease progressors had increases in [¹⁸ F]FDDNP between 5.5% to 11.2% compared to $\leq 3\%$ in nine non-progressors

^aIn some cases a study subsample. AD, Alzheimer's disease; aMCI, amnesic MCI; APOE, Apolipoprotein E; BP, binding potential; CN, cognitively normal; DVR, distribution volume ratio; MCI, mild cognitive impairment; NA, not available; PiB, [¹¹C]Pittsburgh Compound-B; SD, standard deviation; SUVr, standard uptake value ratio.

the detection of early pathological changes and prediction of who will ultimately develop AD and who will maintain cognitive health. From a number of studies, it is clear that PET amyloid imaging shows robust differences in A β levels among groups of AD, MCI and CN individuals. When groups are combined, associations between higher A β and lower cognitive performance, especially episodic memory, emerge consistently across studies. Within diagnostic groups, correlations between A β burden and cognitive performance are less clear in cross-sectional investigations (summarized in Tables 1 and 2). The few longitudinal studies to date that included measures of change in cognitive performance over time provide more convincing evidence that increased A β correlates with greater decline in verbal memory, and perhaps other cognitive measures, such as executive function and mental status.

The potential utility of A β imaging as a clinical tool for early diagnosis of preclinical AD remains limited by its lower specificity due to the high proportion of PiB-positive CN individuals [3,5,28,31,35]. Additional challenges in interpreting a positive amyloid scan are the presence of amyloid plaques in other forms of dementia, for example, Lewy body disease [28], and the fact that A β also binds to intravascular amyloid, as is the case with cerebral amyloid angiopathy [46]. Further, current radiotracers for A β imaging label predominantly fibrillar A β and do not measure soluble forms, providing only a partial quantification of A β burden. Despite these

limitations, A β imaging in combination with information on cognitive function can help inform early detection and diagnosis of AD.

The ways in which joint consideration of A β imaging and cognitive function may help inform prediction of AD and cognitive health are illustrated in Table 4. This simplified table shows that, in the presence of cognitive impairment, A β imaging will help distinguish between A β -positive individuals with MCI who are likely to progress to AD versus A β -negative individuals with MCI who have a much lower risk of progression. A β -negative individuals with apparent cognitive impairment may be misdiagnosed as MCI and convert back to normal, may have a different neurodegenerative disorder or other condition, or may be false negative A β cases due to a different isoform [30]. Similarly, A β imaging may help distinguish between CN individuals with longitudinal decline in memory who are likely to develop AD versus those whose memory decline may be associated with other factors, such as other medical conditions or medications. Whereas A β -positive CN individuals with memory decline greater than expected for age are at increased risk for AD, memory declines in older adults who are A β -negative are more likely attributable to other factors. Finally, CN individuals who are A β -negative and do not show accelerated longitudinal decline in memory can be reassured that they are not likely to develop AD over the next several years. CN individuals who are A β -positive and have stable longitudinal memory

Table 4. Joint consideration of β -amyloid and cognition for prediction of cognitive outcomes

β -Amyloid	Cognitively impaired/MCI	CN with memory decline	CN without memory decline
Positive	Increased risk of AD ^a	Increased risk of AD ^a	Cognitive resilience ^b or preclinical AD?
Negative	Low risk of AD	Low risk of AD	Remain CN

^aSee Table 3 for review of rates of conversion. ^bMaintenance of cognitive health despite β -amyloid pathology. AD, Alzheimer's disease; CN, cognitively normal; MCI, mild cognitive impairment.

performance may represent the group of asymptomatic AD or may not have reached a threshold of pathology where memory decline is evident. These findings, of course, must be interpreted in the context of an individual's age and APOE genotype, as younger CN individuals with A β pathology may not have passed through the risk period for accelerated cognitive decline and dementia. Longitudinal follow-up studies will determine the time course of the development of A β and whether there truly are individuals who are resilient to pathology or in whom the clinical symptoms are delayed. Moreover, comparisons between A β -positive individuals who have stable memory performance and those who show cognitive decline and impairment may lead to identification of factors that promote cognitive resilience despite pathology. The ability to stratify longitudinal trajectories of memory performance by A β will also inform and perhaps revise our definition of what constitutes 'normal aging' in the absence of pathology. Finally, prediction models incorporating other factors, such as APOE genotype, cerebrospinal fluid (CSF) A β and Tau, as well as both regional and network-based spatial measures of brain atrophy on MRI [47] may increase sensitivity and specificity for early identification of AD and cognitive resilience.

In addition to its contributing role in early identification of individuals at greatest risk for AD, amyloid imaging is also aiding in drug development and elucidating the regional distribution and temporal course of the neurobiological changes leading to memory loss and AD. Amyloid imaging informs the selection of participants in therapeutic trials - for example, for anti-A β treatments - and may be useful in monitoring therapeutic response. In one recent trial, an 8.5% decline in A β level was detected in response to an anti-A β treatment [48]. PET amyloid imaging is also being used in combination with CSF and MRI measures to track the temporal course and regional brain changes preceding memory loss. Amyloid deposition is hypothesized to be an early stage of the disease process, with functional and structural brain changes, including hippocampal volume loss, occurring closer to the manifestation of clinical symptoms [49]. Imaging tools provide information throughout the brain, directing attention to the regions showing the earliest amyloid deposition and volumetric changes. In some cases, such as early amyloid deposition in precuneus/posterior

This article is part of a review series on *Amyloid Imaging*. Other articles in the series can be found online at <http://alzres.com/series/amyloidimaging>

cingulate, these imaging findings are focusing more detailed investigation on brain regions that were not included previously in laborious neuropathological evaluations [50,51]. Amyloid imaging also provides the opportunity for prospective assessment of amyloid deposition in relation to changes in cognitive performance and regional brain volumes [47,52]. The ability to track pathology over time using both amyloid imaging and CSF measures of A β [53] will enhance understanding of the temporal sequence of events in parallel and subsequent to amyloid deposition. Such studies may reveal whether there is some threshold beyond which memory impairment is evident and may identify factors that either render some individuals with substantial pathology resilient to disease or promote a delayed onset of clinical symptoms.

Abbreviations

A β , β -amyloid; AD, Alzheimer's disease; APOE, Apolipoprotein E; CN, cognitively normal; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; PET, positron emission tomography; PiB, [¹¹C]Pittsburgh Compound-B.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

This research was supported by the Intramural Research Program of the NIH, National Institute on Aging and N01-AG-3-2124.

Author details

¹Laboratory of Behavioral Neuroscience, NIH Biomedical Research Center, National Institute on Aging, IRP, 251 Bayview Blvd, Room 4B335, Baltimore, MD 21224, USA. ²Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287-0807, USA.

Published: 31 January 2011

References

- O'Brien RJ, Resnick SM, Zonderman AB, Ferrucci L, Crain BJ, Pletnikova O, Rudow G, Iacono D, Riudavets MA, Driscoll I, Price DL, Martin LJ, Troncoso JC: **Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA).** *J Alzheimers Dis* 2009, **18**:665-675.
- Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC: **Neuropathology of nondemented aging: presumptive evidence**

- for preclinical Alzheimer disease. *Neurobiol Aging* 2009, **30**:1026-1036.
3. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolkowski SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE: **Frequent amyloid deposition without significant cognitive impairment among the elderly.** *Arch Neurol* 2008, **65**:1509-1517.
4. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, Price JC, Reiman EM, Skovronsky D, Koeppe RA: **The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.** *Alzheimers Dement* 2010, **6**:221-229.
5. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC: **[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.** *Neurology* 2006, **67**:446-452.
6. Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis CA, Klunk WE, Ferrucci L, Kraut MA, Wong DF: **Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PIB.** *Neurology* 2010, **74**:807-815.
7. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Frapp J, Tochon-Danguy H, Morandau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoek C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL: **Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.** *Neurobiol Aging* 2010, **31**:1275-1283.
8. Hyman BT: **The neuropathological diagnosis of Alzheimer's disease: clinical-pathological studies.** *Neurobiol Aging* 1997, **18**(4 Suppl):S27-32.
9. Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, Grant EA, Berg L: **Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease.** *Neurology* 1996, **46**:707-719.
10. Morris JC: **Mild cognitive impairment and preclinical Alzheimer's disease.** *Geriatrics* 2005, **Suppl**:9-14.
11. Driscoll I, Resnick SM, Troncoso JC, An Y, O'Brien R, Zonderman AB: **Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly.** *Ann Neurol* 2006, **60**:688-695.
12. Galvin JE, Powlishtta KK, Wilkins K, McKeel DW Jr, Xiong C, Grant E, Storandt M, Morris JC: **Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study.** *Arch Neurol* 2005, **62**:758-765.
13. Petersen RC, Morris JC: **Mild cognitive impairment as a clinical entity and treatment target.** *Arch Neurol* 2005, **62**:1160-1163; discussion 1167.
14. Sojkova J, Resnick SM: **In vivo human amyloid imaging.** *Curr Alzheimer Res* 2011 [Epub ahead of print].
15. Klunk WE, Mathis CA: **Amyloid imaging and (what is normal?) aging.** In *Imaging the Aging Brain*. Edited by Jagust WDE. Oxford, USA: Oxford University Press; 2009.
16. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC: **Alzheimer's Disease Neuroimaging Initiative: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.** *Brain* 2009, **132**:1355-1365.
17. Vandenberghe R, Van Laere K, Ivanioiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ: **(18)F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial.** *Ann Neurol* 2010, **68**:319-329.
18. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasic JR, Ye W, Hilton J, Lyketos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ: **In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).** *J Nucl Med* 2010, **51**:913-920.
19. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dykts T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL: **Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.** *Lancet Neurol* 2008, **7**:129-135.
20. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR: **PET of brain amyloid and tau in mild cognitive impairment.** *N Engl J Med* 2006, **355**:2652-2663.
21. Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurtsema G, Windhorst AD, Barkhof F, Scheltens P, Lammertsma AA, van Berckel BN: **Detection of Alzheimer pathology In vivo using both 11C-PIB and 18F-FDDNP PET.** *J Nucl Med* 2009, **50**:191-197.
22. Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB: **Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.** *Neuroimage* 2010, **52**:488-496.
23. Forsberg A, Engler H, Almkvist O, Blomqvist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A: **PET imaging of amyloid deposition in patients with mild cognitive impairment.** *Neurobiol Aging* 2008, **29**:1456-1465.
24. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagnen K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ: **Conversion of amyloid positive and negative MCI to AD over 3 years. An 11C-PIB PET study.** *Neurology* 2009, **73**:754-760.
25. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, De-Kosky ST: **Amyloid imaging in mild cognitive impairment subtypes.** *Ann Neurol* 2009, **65**:557-568.
26. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, Kempainen N, Nagnen K, Kim BC, Tsui W, de Leon MJ: **Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.** *Eur J Nucl Med Mol Imaging* 2008, **35**:2169-2181.
27. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolkowski SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA: **Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.** *J Cereb Blood Flow Metab* 2005, **25**:1528-1547.
28. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL: **Imaging beta-amyloid burden in aging and dementia.** *Neurology* 2007, **68**:1718-1725.
29. Lowe VJ, Kemp BJ, Jack CR Jr, Senjem M, Weigand S, Shiung M, Smith G, Knopman D, Boeve B, Mullan B, Petersen RC: **Comparison of 18F-FDG and PIB PET in cognitive impairment.** *J Nucl Med* 2009, **50**:878-886.
30. Rosen RF, Ciliax BJ, Wingo TS, Gearing M, Dooyema J, Lah JJ, Ghiso JA, Levine H, 3rd, Walker LC: **Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.** *Acta Neuropathol* 2010, **119**:221-233.
31. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA: **APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.** *Ann Neurol* 2010, **67**:122-131.
32. Stern Y: **What is cognitive reserve? Theory and research application of the reserve concept.** *J Int Neuropsychol Soc* 2002, **8**:448-460.
33. Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, Sperling RA, Johnson KA: **Cognition, reserve, and amyloid deposition in normal aging.** *Ann Neurol* 2010, **67**:353-364.
34. Chételat G, Villemagne VL, Pike KE, Baron JC, Bourgeat P, Jones G, Faux NG, Ellis KA, Salvado O, Szoek C, Martins RN, Ames D, Masters CL, Rowe CC: **Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group: Larger temporal volume in elderly with high versus low beta-amyloid deposition.** *Brain* 2010, **133**:3349-3358.
35. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC: **Beta-amyloid imaging and memory in nondemented individuals: evidence for preclinical Alzheimer's disease.** *Brain* 2007, **130**:2837-2844.
36. Tolboom N, van der Flier WM, Yaqub M, Koene T, Boellaard R, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN: **Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment.** *Neurology* 2009, **73**:2079-2085.
37. Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A: **High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.** *Curr Alzheimer Res* 2010, **7**:56-66.
38. Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC: **Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake.** *Arch Neurol* 2008, **65**:1467-1471.
39. Braskie MN, Klunder AD, Hayashi KM, Protas H, Kepe V, Miller KJ, Huang SC, Barrio JR, Ercoli LM, Siddarth P, Satyamurthy N, Liu J, Toga AW, Bookheimer SY, Small GW, Thompson PM: **Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease.** *Neurobiol Aging* 2010, **31**:1669-1678.
40. Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A, Racine C, Miller BL, Jagust WJ: **Cognition, glucose metabolism and amyloid burden in Alzheimer's disease.** *Neurobiol Aging* 2010 [Epub ahead of print].
41. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL,

- Koeppel RA, Mathis CA, Weiner MW, Jagust WJ: **Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.** *Brain* 2009, **132**:1310-1323.
42. Storandt M, Mintun MA, Head D, Morris JC: **Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.** *Arch Neurol* 2009, **66**:1476-1481.
 43. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O'Keefe G, Masters CL, Rowe CC: **Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease.** *Neuropsychologia* 2008, **46**:1688-1697.
 44. Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, Hänninen T, Hallikainen M, Nägren K, Rinne JO, Soininen H: **PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment.** *Dement Geriatr Cogn Disord* 2008, **26**:378-383.
 45. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA: **Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.** *Arch Neurol* 2009, **66**:1469-1475.
 46. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM: **Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.** *Ann Neurol* 2007, **62**:229-234.
 47. Davatzikos C, Xu F, An Y, Fan Y, Resnick SM: **Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index.** *Brain* 2009, **132**:2026-2035.
 48. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M: **11C-PIB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.** *Lancet Neurol* 2010, **9**:363-372.
 49. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: **Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.** *Lancet Neurol* 2010, **9**:119-128.
 50. Iacono D, O'Brien R, Resnick SM, Zonderman AB, Pletnikova O, Rudow G, An Y, West MJ, Crain B, Troncoso JC: **Neuronal hypertrophy in asymptomatic Alzheimer disease.** *J Neuropathol Exp Neurol* 2008, **67**:578-589.
 51. Riudavets MA, Iacono D, Resnick SM, O'Brien R, Zonderman AB, Martin LJ, Rudow G, Pletnikova O, Troncoso JC: **Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons.** *Neurobiol Aging* 2007, **28**:1484-1492.
 52. Aisen PS: **Predictors of progression in the ADNI-MCI cohort.** *Alzheimers Dementia* 2010, **6**:S63.
 53. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM: **Inverse relation between *In vivo* amyloid imaging load and cerebrospinal fluid Abeta42 in humans.** *Ann Neurol* 2006, **59**:512-519.
 54. Grimmer T, Henriksen G, Wester HJ, Forstl H, Klunk WE, Mathis CA, Kurz A, Drzezga A: **Clinical severity of Alzheimer's disease is associated with PIB uptake in PET.** *Neurobiol Aging* 2009, **30**:1902-1909.

doi:10.1186/alzrt62

Cite this article as: Resnick SM, Sojkova J: **Amyloid imaging and memory change for prediction of cognitive impairment.** *Alzheimer's Research & Therapy* 2011, **3**:3.